[CAS NO. 2135696-72-7] Tarlox-TKI
PRODUCTS SPECIFICATIONS [2135696-72-7]
DESCRIPTION [2135696-72-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 461.74 |
| Molecular Formula | C19H18BrClN6O |
| SMILES | BrC1=C(Cl)C=CC(NC2=NC=NC3=CN=C(NC(/C=C/CN(C)C)=O)C=C32)=C1 |
Summary
Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan- ErbB TKI (Tarlox-TKI) [1] .
IC50 & Target
|
EGFR |
In Vitro
Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 216.57 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1657 mL | 10.8286 mL | 21.6572 mL |
| 5 mM | 0.4331 mL | 2.1657 mL | 4.3314 mL |
| 10 mM | 0.2166 mL | 1.0829 mL | 2.1657 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
